About Kat Richardson
Articles by Kat Richardson
ViPOR Study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Oct 15, 2024
CAR T-Cell Therapy Advances in Large B Cell LymphomaJun 18, 2024
Understanding Follicular Lymphoma (Part 4): Q&A SessionMay 02, 2024
Understanding Follicular Lymphoma (Part 3) with Dr. Sarah RutherfordApr 30, 2024
Understanding Follicular Lymphoma (Part 2) with Dr. Talal HilalApr 29, 2024
Understanding Follicular Lymphoma (Part 1) with Dr. Samuel YamshonApr 25, 2024
Expanding Treatment Horizons with ImmunotherapyApr 15, 2024
Odronextamab for Lymphoma: FDA Delays Approval Decision, Trials Still EnrollingApr 10, 2024
Exploring High-Risk Follicular Lymphoma through GenomicsApr 08, 2024
Advancing CNS Lymphoma Treatment and ResearchMar 31, 2024
Zanubrutinib (Brukinsa) Receives FDA Approval for Follicular Lymphoma TreatmentMar 25, 2024
Treatment Options for Relapsed/Refractory DLBCLFeb 28, 2024- ASH 2023: Promising Ibrutinib Results for DLBCL with Central Nervous System InvolvementFeb 14, 2024
ASH 2023: MD Anderson's Chemotherpy-Free Study for DLBCLJan 31, 2024
ASH 2023: Contrasting Outcomes in Adult and Pediatric Centers for B-Cell Lymphoma PatientsJan 29, 2024- ASH 2023: Circulating Tumor DNA as a Detection Tool Following DLBCL TherapyJan 24, 2024
ASH 2023: Predicting Drug Toxicity in CAR T-Cell Therapy RecipientsJan 15, 2024
ASH 2023: Older NHL Patients Experience Improved Quality of Life Throughout TreatmentJan 08, 2024
ASH 2023: Older NHL Patients Experience Improved Quality of Life Throughout TreatmentJan 01, 2024
ASH 2023: Trial of an Education Video to Help CAR-T Cell Therapy RecipientsDec 27, 2023
ASH 2023: Trial of an Education Video to Help CAR-T Cell Therapy RecipientsDec 27, 2023
ASH 2023: Loncastuximab for High-Risk Relapsed/Refractory Follicular LymphomaDec 22, 2023
ASH 2023: Fighting DLBCL by Attacking the MicroenvironmentDec 22, 2023
ASH 2023: A Shift in Standard of Care for Older Patients with Advanced Stage Hodgkin LymphomaDec 22, 2023
